07/10/2018 16:17:00

CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Oct. 07, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Cocrystal Pharma, Inc. f/k/a BioZone Pharmaceuticals, Inc. (NASDAQCM: COCP)

Class Period: September 23, 2013 - September 7, 2018

Lead Plaintiff Deadline: November 19, 2018

Join the action: https://www.zlk.com/pslra-1/cocrystal-pharma-inc-loss-form?wire=3

Allegations: Cocrystal Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Cocrystal Pharma, Inc. class action contact jlevi@levikorsinsky.com.

AbbVie, Inc. (NYSE: ABBV)

Class Period: October 25, 2013 - September 18, 2018

Lead Plaintiff Deadline: November 20, 2018

Join the action: https://www.zlk.com/pslra-1/abbvie-inc-loss-form?wire=3

About the lawsuit: During the class period, AbbVie, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

To learn more about the AbbVie, Inc. class action contact jlevi@levikorsinsky.com.

Alnylam Pharmaceuticals, Inc. (NASDAQGS: ALNY)

Class Period: February 15, 2018 - September 12, 2018

Lead Plaintiff Deadline: November 26, 2018

Join the action: https://www.zlk.com/pslra-1/alnylam-pharmaceuticals-inc-loss-form?wire=3

About the lawsuit: Alnylam Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.

To learn more about the Alnylam Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

250x148_zlk.jpg

Related content
06 May - 
Alector Announces First Alzheimer’s Disease Patient Dos..
12 Apr - 
New Research: Key Drivers of Growth for Sonos, Alnylam ..
01 Apr - 
Alector Initiates Phase 1 Trial of AL003 for the Treatm..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week

Related stock quotes

AbbVie Inc 78.69 -0.3% Stock price decreasing
Alnylam Pharmaceuticals .. 70.09 -1.6% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 June 2019 21:03:33
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB5 - 2019-06-16 22:03:33 - 2019-06-16 21:03:33 - 1000 - Website: OKAY